U.S. Markets closed

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
78.56+1.61 (+2.09%)
At close: 4:00PM EDT
People also watch
TSROPBYIKITEBLUEICPT

Clovis Oncology, Inc.

5500 Flatiron Parkway
Suite 100
Boulder, CO 80301
United States
303-625-5000
http://www.clovisoncology.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees278

Key Executives

NameTitlePayExercisedAge
Mr. Patrick J. Mahaffy MACo-Founder, Chief Exec. Officer, Pres and Exec. Director788.62kN/A54
Dr. Gillian C. Ivers-Read BScCo-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations735.17kN/A63
Mr. Daniel W. Muehl CPASr. VP of Fin. and Principal Financial & Accounting Officer492.36kN/A53
Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPMChief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance724.92kN/A49
Mr. Corwin Dale HooksChief Commercial Officer and Sr. VP585.27kN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Corporate Governance

Clovis Oncology, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 6. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.